Abstract-Granulocyte colony stimulating factor (G-CSF) is a multi-modal hematopoietic growth factor, which also has profound effects on the diseased CNS. G-CSF has been shown to enhance recovery from neurologic deficits in rodent models of ischemia. G-CSF appears to facilitate neuroplastic changes by both mobilization of bone marrow-derived cells and by its direct actions on CNS cells. The overall objective of the study was to determine if G-CSF administration in a mouse model of Alzheimer's disease (AD) (Tg APP/PS1) would impact hippocampal-dependent learning by modifying the underlying disease pathology. A course of s.c. administration of G-CSF for a period of less than three weeks significantly improved cognitive performance, decreased ␤-amyloid deposition in hippocampus and entorhinal cortex and augmented total microglial activity. Additionally, G-CSF reduced systemic inflammation indicated by suppression of the production or activity of major pro-inflammatory cytokines in plasma. Improved cognition in AD mice was associated with increased synaptophysin immunostaining in hippocampal CA1 and CA3 regions and augmented neurogenesis, evidenced by increased numbers of calretinin-expressing cells in dentate gyrus. Given that G-CSF is already utilized clinically to safely stimulate hematopoietic stem cell production, these basic research findings will be readily translated into clinical trials to reverse or forestall the progression of dementia in AD. The primary objective of the present study was to determine whether a short course of G-CSF administration would have an impact on the pathological hallmark of AD, the age-dependent accumulation of A␤ deposits, in a transgenic mouse model of AD (APP؉ PS1; Tg). A second objective was to determine whether such treatment would impact cognitive performance in a hippocampal-dependent memory paradigm. 
Granulocyte colony stimulating factor (G-CSF; filgastrim) is one of several hematopoietic growth factors (HGFs) or colony stimulating factors (CSFs) that control the production of circulating blood cells by the bone marrow. G-CSF is produced by endothelium, macrophages, and a number of other immune cells. G-CSF and its receptor have also been reported to be expressed in neurons and neural progenitor cells that reside in the hippocampal neurogenic niche (Schneider et al., 2005) . Although G-CSF has been used primarily as an agent to treat leukopenia, the agent has been studied in animal models of stroke where it has been reported to reduce brain damage and improve outcome (Schabitz et al., 2003; Six et al., 2003; Shyu et al., 2006; Solaroglu et al., 2006) . Several ongoing clinical trials are evaluating the effectiveness and safety of G-CSF for treatment of ischemic stroke, and results are still pending (Schabitz and Schneider, 2006) . It has also been used experimentally to treat myocardial infarction in humans (Takano et al., 2003; Kuethe et al., 2004; Nienaber et al., 2006; Ripa et al., 2006; Suzuki et al., 2006) . In addition, G-CSF has putative neuroprotective actions (e.g. anti-apoptotic and/or neurogenic) independent of its regulation of granulocyte differentiation and stem cell mobilization (Schabitz et al., 2003; Gibson et al., 2005; Solaroglu et al., 2006) . G-CSF has also been shown to modulate systemic immune responses by inhibiting pro-inflammatory cytokines. Animal, volunteer, and patient studies have all shown that G-CSF reduces inflammatory activity by inhibiting the production or activity of the main inflammatory mediators interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-␣), and interferon gamma (IFN-␥) (Hartung, 1998) . Importantly, decreased plasma levels of G-CSF (and other hematopoietic factors) have been linked to Alzheimer's disease (AD) and are in fact predictive of conversion from mild cognitive impairment (MCI) to AD (Ray et al., 2007) .
One of the mechanisms by which G-CSF hastens recovery from ischemic neurologic deficits in animal models of stroke is related to increased activation of resident microglia but not to increased mobilization of marrow-derived microglia (Komine-Kobayashi et al., 2006) . However, many of the microglia that infiltrate the core of beta-amyloid (A␤) plaques in transgenic (Tg) mouse models of AD have been shown to originate from the bone marrow (Malm et al., 2005; Simard et al., 2006) . Both A␤1-40 and A␤1-42 are effective in triggering this chemoattraction. Although resident microglia are clearly activated in response to A␤ deposition, the bone marrow-derived microglia appear to be very efficient in reabsorption of these A␤ deposits (Simard et al., 2006) . Furthermore, penetration of bone marrow-derived cells into the brain can be boosted by microinjection of lipopolysaccharide into hippocampus (H) of AD mice (Malm et al., 2005) . This procedure significantly increased the number of bone marrow-derived cells in aged AD mice and resulted in decreased hippocampal A␤ burden (Malm et al., 2005) . Administration of G-CSF has been reported to improve cognitive performance in Tg2576 mice without reduction of total brain amyloid burden (Tsai et al., 2007) . That study also reported an increased proliferation of cells around the amyloid plaques, based on BrdU labeling. The authors indicated that the BrdU-labeled cells co-expressed neuronal markers and suggested hematopoietic stem/progenitor cells trans-differentiated into neurons around the plaques (Tsai et al., 2007) . In this context, our prior review of the literature has raised interesting and paradoxical issues that warrant the systematic study of G-CSF and other HGFs for treatment of AD (Sanchez-Ramos et al., 2008) .
EXPERIMENTAL PROCEDURES Animals
Mice were generated from a cross between F6 generation mice heterozygous for the mutant APPK670N, M671L gene (i.e. the APPsw, Swedish mutation derived from Tg2576 mice), and littermate mutant PS1 (6.2 line) mice bearing the M146V mutation (all mice contained a mixed background of C57B6, B6D2F1, SJL, and SW). Mice were initially genotyped at the time of weaning and then had a confirmatory genotyping at 4 months of age. A total of 52 mice in two age-based cohorts composed the behavioral studies. Cohort 1 (nϭ25) ranged from 13 to 15 months old and cohort 2 (nϭ27) ranged from 7 to 9 months old. The behavioral study initially involved only cohort 1 mice. However, upon seeing a strong cognitive-enhancing effect of G-CSF in this cohort, we decided to repeat the study in a second cohort of aged mice (cohort 2) to confirm our behavioral results. A total of 24 APPϩ PS1 double Tg mice (e.g. mice bearing both APPsw and PS1 mutations) and 28 non-Tg littermates were distributed between the two cohorts. A third cohort of APPϩ PS1 mice (nϭ16) was utilized to generate chimeric mice with GFP-expressing bone marrow. Mice were housed and maintained in a specific pathogenfree facility under a 12-h light/dark cycle, with ad libitum access to rodent chow and water. All experiments conformed to guidelines for the ethical use of animals as provided by the Association for the Assessment and Accreditation of Laboratory Animal Care, International (AAALAC #000434). The number of animals utilized was based on statistical power analysis and all means were taken to reduce suffering. The protocol was approved by the IACUC of the University of South Florida.
Chimeric Tg APP/PS1 mice with bone marrow derived from Tg "green mice"
Sixteen APPϩ PS1 mice from the same colony (2 months old) were lethally irradiated with 10 Gy total body irradiation (delivered in two fractions of 5 Gy at dose rate of 1.03 Gy/min in a Gammacell 40 Extractor (Nordion International, Inc., Ontario, Canada) (Furuya et al., 2003) ). This was followed by rescue with a bone marrow transplant (8ϫ10 6 mononuclear cells in 0.2 ml) from Tg GFP mice (C57BL/6-Tg [ACTB-EGFP] 1Osb/J, 003291; the Jackson Laboratory, Bar Harbor, ME, USA) infused via tail vein. Bone marrow-derived cells in the rescued mice were readily tracked by virtue of their green fluorescence. Examination of blood smears from tail clippings for the presence of green monocytes confirmed successful engraftment. An average of 75% of the irradiated mice had successful engraftment and exhibited GFPϩ mononuclear cells in their peripheral blood.
G-CSF dose and administration schedule
G-CSF, a natural human glycoprotein, exists in two forms of a 174-and 180-amino-acid-long protein of molecular weight 19,600 g per mol. The more-abundant and more-active 174-amino acid form has been used in the development of pharmaceutical products by recombinant human DNA (rhDNA) technology. Filgrastim (Neupogen ® , Amgen, Inc., Thousand Oaks, CA, USA), one of three proprietary G-CSF compounds, was utilized in the present study.
The dose of G-CSF (250 g/kgϫ6 doses) administered in the present study was lower than that reported to be effective in mobilizing bone marrow in a rat model of stroke (300 g/kgϫ10 days) but higher than that utilized by others in rodent models of stroke (Schabitz et al., 2003 , Six et al., 2003 , Solaroglu et al., 2006 and in a recently published report on the treatment of memory impairment in a mouse model of AD (50 g/kg s.c. for 5 days) (Tsai et al., 2007) . The schedule of administration of G-CSF was one injection s.c. every other day for 3 weeks. In the experiments in which behavioral testing was performed before and after administration of G-CSF, the drug continued to be given on alternate days during the final behavioral testing. Dilution of G-CSF was in 5% dextrose as recommended by the manufacturer (Amgen, Inc.). Vehicle (5% dextrose) was administered to control Tg and non-Tg groups.
Behavioral testing
Spatial working memory was assessed in a "win-stay" version of the radial arm water maze (RAWM) task. Animals were pretreatment tested for 8 consecutive days in the RAWM task, and then each genotype (non-transgenic [NT], Tg) was divided into two groups behaviorally balanced in pre-treatment RAWM performance. For Tg mice, blood A␤ levels following pre-treatment testing were also utilized to balance treatment and control Tg groups. Beginning at two weeks into treatment, all mice were re-tested in the RAWM for 4 consecutive days. For RAWM testing, an aluminum insert was introduced into a 100 cm pool in order to divide the pool into six equally spaced swim arms (30.5 cm length 19 cm width) radiating from a central circular swim area (40 cm diameter). The insert extended 5 cm above the surface of the water, allowing the mice to easily view surrounding visual cues, which were generously placed outside of the pool. Visual/spatial cues consisted of large brightly colored 2D and 3D objects, including a beach ball, poster, and inflatable pool toys. During testing, the pool water was maintained at 23-27°C. In one of the arms, a transparent 9 cm submerged escape platform was placed 1.5 cm below the water near the wall end. Each mouse was given five 1-min trials per day. The last of the four consecutive acquisition trials (Trial 4, T4) and a 30-min delayed retention trial (Trial 5, T5) are indices of working memory. On any given day, the escape platform location was placed at the end of one of the six arms, with the platform moved to a different arm in a semi-random fashion for each day of testing. In contrast to the stationary platform of Morris water maze, moving the escape platform forced the animal to learn a new platform location daily, therefore evaluating working memory. On each day, different start arms for each of the five daily trials were selected from the remaining five swim arms in a semirandom sequence that involved all five arms. For any given trial, the mouse was placed into that trial's start arm, facing the center swim area, and given 60 s to find the platform. When the mouse made an incorrect choice, it was gently pulled back to that trial's start arm and an error was recorded. An error was also recorded if the mouse failed to make a choice in 20 s (in which case it was returned to that trails start arm), or if the animal entered the platform-containing arm, but failed to locate the platform. A 30-s stay was given once the mouse had found the platform. If the mouse did not find the platform within a 60-s trial, it was guided by the experimenter to the platform, allowed to stay for 30 s, and was assigned a latency of 60 s. Both errors (incorrect arm choices) and escape latency were recorded for each daily trial.
Sample preparation and immunohistochemistry
At the conclusion of the behavioral testing (approximately 3 weeks into treatment and at 14 -15 months of age for the first cohort of mice and at 8 -9 months for the second cohort), mice were anesthetized under deep chloral hydrate (10%) anesthesia. Blood was collected intracardially and a plasma sample was stored at Ϫ80°C for later analysis of A␤ levels. After transcardial perfusion of the brain with 0.1 M phosphate-buffered saline (PBS), the brain was removed and bisected parasagittally. Further, the right hemisphere was dissected into two pieces (frontal and caudal brains). These brain pieces were immediately frozen on dry ice and stored at Ϫ80°C for determination of A␤ levels by ELISA. The left hemisphere was placed in 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4) overnight. Like the right hemisphere, the brain was dissected into two pieces (frontal and caudal brains) and the frontal piece was transferred to a graded series of sucrose solutions (10%, 20%, and finally 30%). Quarter brains that had been stored in 30% sucrose solution were removed, rinsed in dH 2 O, and frozen on the stage of a sliding microtome.
The caudal part of the left hemisphere was routinely embedded in paraffin with 24 h processing. For paraffin sectioning, five coronal sections (per set) with a 150 m interval were cut at a thickness of 5 m in H and entorhinal cortex (EC), bregma Ϫ2.92 to Ϫ3.64 mm (Paxinos and Franklin, 2001) . Four sets of five sections from H and EC were prepared for analyses of A␤ and Iba1 (ionized calcium-binding adapter molecule 1). Immunohistochemical staining was performed following the manufacturer's protocol using a Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA, USA) coupled with the diaminobenzidine reaction, except that the biotinylated secondary antibody step was omitted for A␤ immunohistochemical staining. The following primary antibodies were used for immunohistochemical staining: a biotinylated human amyloid-␤ monoclonal antibody (clone 4G8; 1:200, Covance Research Products, Emeryville, CA, USA), an Iba-1 polyclonal antibody (1:1000, Wako, Osaka, Japan), and rabbit synaptophysin polyclonal antibody (undiluted, DAKO, Carpinteria, CA, USA).
For the experiments using chimeric Tg APPϩ PS1 mice, no behavioral analysis was performed. At the end of 2 weeks of G-CSF treatment, animals were anesthetized and perfused as above. Brains were bisected parasagitally; with one-half for A␤ level determinations by ELISA and the other half for fluorescence immunohistochemistry. The left hemisphere was placed in 4% paraformaldehyde in 0.1 M PB (pH 7.4) overnight. The hemisphere was dissected into two pieces (frontal and caudal brains) and the frontal piece was transferred to a graded series of sucrose solutions (10%, 20%, and finally 30%). Quarter brains that had been stored in 30% sucrose solution were removed, rinsed in dH 2 O, and frozen on the stage of a sliding microtome. Antibodies to GFP (chicken anti-GFP 1:1250, Chemicon International, Temecula, CA, USA) were used to enhance the GFPϩ signal from bone marrow-derived cells that accumulated around amyloid deposits. The secondary antibody was Alexa Fluor 488 -labeled goat anti-chicken IgG, 1:400 (Invitrogen Corp., Carlsbad, CA, USA). For calretinin immunofluorescence, sections were blocked in PBSϩ (PBS, 10% normal goat serum, 1% TX-100, 1 M lysine) for 1 h at 4°C and incubated overnight at 4°C in rabbit anti-calretinin 1:2500 (Swant International, Bellinzona, Switzerland) in PBS. Sections were washed in PBS and incubated in goat anti-rabbit IgG Alexa Fluor 488 (Invitrogen Corp.) and coated with Vectorshield mounting medium (Invitrogen Corp.). Labeled cells were visualized with fluorescence microscopy (IX2 inverted microscope; Olympus, Tokyo, Japan) using appropriate filters or with a confocal microscope (LSM 510; Carl Zeiss, Inc., Thornwood, NY, USA). Digital images were captured with either the DP-70 digital camera system (Olympus) or by collecting Z-stacks of the confocal images (Carl Zeiss, Inc.).
Proliferation assay for hippocampal neural stem/progenitor cells (NSC) in vitro
NSC from adult H of C57BL mice were isolated and maintained in cell culture in the presence of EGF and bFGF using standard methods as described previously in our laboratory (Sava et al., 2007) . G-CSF was added to hippocampal NSC in basal media containing DMEMϩ10% FBS for 48 h (in absence of EGF and bFGF), and incorporation of [ 3 H]-thymidine was measured as previously described (Sava et al., 2007) . Briefly, at various intervals after G-CSF addition (0, 24, 48, and 72 h), 37,000 Bq/ml (500 pmol/m) [ 
Estimates of hippocampal neurogenesis in vivo
Unbiased estimates of the number of immature neurons in dentate gyrus (DG) were made by counting calretinin-immunoreactive cells in serially sectioned H according to the method previously described (Shors et al., 2001 (Shors et al., , 2002 . Briefly, positively labeled cells were counted in every 6th section (each section separated by 180 m) using a modification to the optical dissector method; cells on the upper and lower planes were not counted to avoid counting partial cells. The number of calretininϩ cells counted in every 6th section was multiplied by 6 to get the total number of calretininϩ cells in the DG.
A␤ burden, Iba1 (microgliosis) burden, and synaptophysin immunostaining by quantitative image analyses
Images were acquired as digitized tagged-image format files to retain maximum resolution using an Olympus BX60 microscope with an attached digital camera system (DP-70, Olympus), and digital images were routed into a Windows PC for quantitative analyses using SimplePCI software (Compix, Inc. Imaging Systems, Cranberry Township, PA, USA). Images of five sections (each 5 m thick and 150 m apart) were captured from serially sectioned EC and H and a threshold optical density was obtained that discriminated staining from background. Each anatomic region of interest was manually edited to eliminate artifacts. For A␤ and Iba1 (microgliosis) burden analyses, data are reported as the percentage of labeled area captured (positive pixels) divided by the full area captured (total pixels). Bias was eliminated by analyzing each entire region of interest (H and EC) represented by the sampling of five sections per region. Stereological equipment was not used. To evaluate synaptophysin immunostaining, after the mode of all images was converted to gray scale, the average optical density of positive signals from each image was quantified in the CA1 and CA3 regions of H as a relative number from zero (white) to 255 (black) and expressed as mean intensity of synaptophysin immunoreactivity. Each analysis was done by a single examiner blinded to sample identities.
A␤ ELISA
Hippocampal and cortical levels of soluble A␤1-40 and A␤1-42 were measured by ELISA. Briefly, 30 mg brain tissues were homogenized in 400 l RIPA buffer (100 mM Tris [pH 8.0], 150 mM NaCl, 0.5% DOC, 1% NP-40, 0.2% SDS, and one tablet proteinase inhibitor per 100 ml) (S8820, Sigma, St. Louis, MO, USA), and sonicated for 20 s on ice. Samples were then centrifuged for 30 min at 27,000ϫg at 4°C, and supernatants were transferred into new screw cap tubes. The supernatants obtained from this protocol were then stored at Ϫ80°C for determination of soluble A␤ levels using ELISA kits (KHB3482 for 40, KHB3442 for 42, Invitrogen). Standards and samples were mixed with detection antibody and loaded on the antibody pre-coated plate as the designated wells. HRP-conjugated antibody was added after washing, substrates were added for colorimetric reaction, and then stopped with sulfuric acid. Optical density was obtained and concentrations were calculated according to the standard curve. Plasma A␤1-40 and -42 levels were determined with the same protocol and using the same ELISA kits.
Cytokine analyses
For blood samples taken at euthanasia from cohort 1 of the behavioral study, plasma levels of 23 cytokines were measured using Bio-Rad Bio-Plex kits (Bio-Rad, catalogue # 171F11181). Hippocampal levels of these 23 cytokines were also determined with the same protocol. Samples and standards were prepared using company protocols with the initial concentration of standards ranging from 32 ng/ml to 1.95 pg/ml. Plasma samples were prepared for analysis by diluting 1 vol of the serum sample with three volumes of the Bio-Plex mouse sample diluent. Using the microplate readout, each cytokine level was calculated based on its own standard curve.
Statistical analysis
Behavioral performance was statistically evaluated (Statistica) to determine group differences based on genotype and treatment with G-CSF compared to placebo. The RAWM data were analyzed using both one-way ANOVAs and two-way repeated measure ANOVAs. Prior to analysis, the RAWM behavioral data were divided into 2-day blocks to aid in data presentation and analysis. After ANOVA analysis, post hoc pair-by-pair differences between groups (planned comparisons) were resolved using the Fisher's LSD test. Pre-vs. post-GCSF behavioral measures were statistically evaluated using paired Student's t-test, with Bonferroni's correction for multiple comparisons, as appropriate. Neurohistologic and neurochemical analyses were performed using ANOVA. All group data are presented as meanϮSEM. Group and all comparisons were considered significant at PϽ0.05.
RESULTS

G-CSF reverses memory impairment in aged AD Tg mice
The APPϩ PS1 (Tg) mice from the colony used in this study have been previously shown to be cognitively impaired in a variety of tasks by 5 months of age (Jensen et al., 2005; Costa et al., 2007) . To confirm that the 13-14 month old and the 8 month old Tg mice to be treated with G-CSF were impaired in working memory, Tg and NT littermates were tested in the RAWM task. Since there were no differences in RAWM performance for either Tg or NT mice between the two cohorts of mice, behavioral data from each genotype were combined for all statistical analysis. With both cohorts of mice thus combined, performance during the last block of pre-treatment testing showed clear impairment of Tg mice during working memory trials T4 and/or T5 for both errors and latency measures (Fig. 1A) . Immediately thereafter, Tg mice (nϭ24) and NT mice (nϭ28) were each divided into two groups (nϭ12-14 per group) balanced in behavioral performance and blood A␤ levels. For each group, G-CSF (or vehicle) was administered for two weeks, with injections continued for RAWM re-testing during the third week. The large number of mice being behaviorally evaluated required two separate cohorts of mice (the 13-14 month old and 8 month old mice), with each cohort a complete study separately since all four groups were included. Though data presentation in this report involves combined cohorts 1 and 2, it is important to note that separate statistical analysis from each group yielded identical Tg and G-CSF treatment effects, thus, the beneficial effects of GCSF that we currently report were duplicated in two independent cohorts of mice that differed in age by 5 months.
At RAWM re-testing, G-CSF treatment had no effect on the already excellent performance of NT mice across multiple RAWM measures, while the same G-CSF treatment resulted in marked and consistent improvement in the RAWM performance of Tg mice ( Figs. 1 and 2 ). During the final day of RAWM testing, control Tg mice could not reduce their number of errors or escape latency between Trial 1 (T1; the naïve trial) and working memory T5 (Fig.  1B, C) . By contrast, Tg mice treated with G-CSF (Tg/ GCSF) showed a highly significant reduction in both errors and latency between T1 and T5. Performance of Tg/GCSF mice was in fact comparable to that of both NT groups. When T5 memory retention was evaluated for the last block of testing (Fig. 1C, E) , Tg control mice once again exhibited significant memory impairment compared to all other groups, while Tg/GCSF mice performed much better and comparable to both NT groups.
As another index of memory performance, pre-treatment versus during-treatment T5 working memory was evaluated for each group. Irrespective of whether errors (Fig. 2, upper) or escape latency (Fig. 2, lower) was assessed, GCSF treatment did not further improve upon the already excellent memory performance of NT mice seen during pre-treatment testing. Tg controls also could not improve upon the impaired pre-treatment working memory performance of Tg mice when tested during ensuing placebo treatment (Fig. 2) . By sharp contrast, Tg/GCSF mice showed significantly improved memory performance during GCSF treatment compared to the high pre-treatment level of errors and escape latencies in Tg mice (Fig. 2) .
G-CSF reduces brain A␤ deposition and A␤ levels in Tg mice
After completion of the behavioral testing, animals were euthanized, a blood sample was taken, then half of each brain was processed for quantitative immunohistochemical determination of total amyloid deposition in situ and the Fig. 1 . G-CSF treatment reverses working memory impairment of Tg mice. (A) Tg mice were impaired in working (short-term) memory performance prior to G-CSF treatment. Performance during the last block of pre-testing in the RAWM task revealed clear impairment of Tg mice during working memory trials T4 and/or T5, and for both errors and latency. ** PϽ0.0001 between groups for that trial. Tg and NT mice were then divided into two groups balanced in behavioral performance and blood A␤ levels. (B, D) On the last of four test days, and at 2½ weeks into G-CSF treatment, Tg control mice could not improve their error (B) and escape latency (D) performance from naïve T1 to the T5 memory retention trial. By contrast, Tg/GCSF mice showed a significant reduction in errors from T1 to T5. NT mice also showed highly significant T1 vs. T5 decreases in both errors and latency, with G-CSF unable to improve upon the already excellent performance level of NT mice. * PϽ0.001, ** PϽ0.00005 for T1 vs. T5. (C, E) For the final 2-day block of testing concurrent with treatment, Tg control mice were impaired versus all other groups in both errors (C) and latency (E). By contrast, Tg/GCSF mice performed similar to NT mice and substantially better the Tg controls. ** PϽ0.005 or higher level of significance versus other three groups; † PϽ0.05 vs. NT group). For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.
other half processed for assessment of soluble A␤ levels. Compared to controls, Tg mice of cohort 1 (14.5 months old) treated with G-CSF exhibited highly significant reductions of 39% and 42% in A␤ deposits within H and EC, respectively (Fig. 3A) . Photomicrographic examples of A␤ immunostaining from both of these brain areas are presented in Fig. 3B . A reduction in size and extent of brain A␤ deposits is qualitatively evident in G-CSF-treated Tg mice compared to Tg controls. The younger cohort 2 (8.5 month of age) also exhibited a highly significant 36% reduction of A␤ deposits in both brain areas (Fig. 3A) , though the A␤ burden in salinecontrol Tg mice was less than in the older mice of cohort 1.
Analysis of soluble A␤ levels from H and plasma of Tg mice from both the 14.5 and 8.5 month cohorts revealed no group differences between cohorts. As such, data from Tg and Tg/GCSF mice in both cohorts were combined for presentation. Tg mice treated with G-CSF exhibited a significant 69% reduction in hippocampal A␤1-40 levels (Fig.  3C) . Similarly, soluble A␤1-42 levels in H were reduced 49% (nearly significant) by GCSF treatment. Soluble A␤ levels in frontal cortex of Tg mice were unaffected by G-CSF treatment (data not shown). Plasma levels of both A␤1-40 and A␤1-42 were also not affected by G-CSF treatment (Fig. 3D) .
Plasma and brain cytokine levels were analyzed from the animals in cohort 1 (aged 14.5 months at euthanasia). In NT mice, no effect of G-CSF on any of the 23 plasma cytokines was observed (data not shown). Twelve out of the 23 cytokines measured were significantly elevated in Tg control mice (Table 1) . However, Tg mice receiving G-CSF showed normal levels in all but one of the 12 plasma cytokines which were elevated in untreated animals (Table 1) . By contrast, hippocampal levels of inflammatory cytokines were not impacted by G-CSF treatment (data not shown); this was true for both NT and Tg mice treated with G-CSF. Thus, GCSF treatment did not result in a global inflammatory response but rather, may have selectively attenuated the elevated plasma cytokine levels occurring in untreated APPϩ PS1 mice. Interestingly, hG-CSF treatment reduced levels of endogenous G-CSF in plasma of NT and Tg mice collectively, comparing pretreatment vs. post-treatment levels (521Ϯ93 vs. 321Ϯ37 ng/ml PϽ0.05, paired t-test). This likely reflects the functionality of hG-CSF in mice and a consequent downregulation of endogenous G-CSF production. A separate determination of hG-CSF in hippocampal tissue from Tg/ GCSF mice revealed measurable levels, indicating that administered hG-CSF had indeed entered the brain.
G-CSF increases microglial burden in Tg mice
It was hypothesized that the most likely mechanism responsible for the marked reduction of brain A␤ deposits was related to the extent and distribution of microglial activity. Therefore, measurement of the total microglial burden was performed by quantitative immunohistochemical studies of Iba1 expression in H and EC from animals in cohort 2 (8 -9 months old at euthanasia). Iba1 is a macrophage/microglia-specific calcium-binding protein expressed in both ramified and resting microglia as well as in activated microglia and macrophages (Imai and Kohsaka, 2002) . G-CSF treatment to NT mice had no effect on Iba-1 burdens in H and EC (Fig. 4A ). Compared to both groups of NT mice, Tg control mice exhibited a substantial elevation in microglial burdens. G-CSF administration to Tg mice resulted in a further increase in microglial burdens above Tg control levels, as indicated by quantitative measures of Iba1 immunoreactivity in both the H (117%) and EC (120%) (Fig. 4A) . Qualitative analysis of brain sections revealed the expected microgliosis in Tg compared to NT mice (Fig. 4B) . The Iba1 immunoreactive cells were distributed around amyloid plaques in both H and EC of Tg mice (H is shown in Fig. 4B) , with G-CSF treatment resulting in an observable increase in microglial burdens.
Effects of G-CSF in chimeric Tg APP/PS1 mice
To determine whether infiltration of bone marrow-derived cells into brain contributed to the microgliosis, a chimeric Tg APPϩ PS1 mouse was generated. Following whole Comparing the last day of pre-testing to the last day of testing with concurrent G-CSF administration, mice in both NT groups showed continuing excellent performance irrespective of G-CSF treatment. Tg control mice exhibited consistently poor performance for both pre-and during-treatment testing. By sharp contrast, Tg mice treated with G-CSF showed significant improvements in both errors and latency during G-CSF treatment. Pre-treatment meanϮSEM values are for all animals in that group. * PϽ0.05, ** PϽ0.01 for pre-treatment versus during-treatment performance (paired t-test). For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article. body irradiation and i.v. infusion of fresh suspensions of mononuclear cells from GFPϩ bone marrow at 2 months of age, 11 of 16 Tg APPϩ PS1 mice were successfully rescued by the bone marrow transplantation. Examination of tail vein blood at age 4 and 6 months revealed that all mononuclear cells expressed GFPϩ, indicating successful engraftment of the marrow by the GFPϩ stem/progenitor cells. These mice were then allowed to mature to the age when brain amyloid levels/deposits interfere with cognitive function (6 -8 months). At this time, blood levels of soluble A␤1-40 were measured and it was discovered that three of the mice did not express A␤. The eight surviving chimeric AD mice were divided into two groups (nϭ4 per group), one of which received G-CSF injections s.c. for 2 weeks and the other of which received vehicle control (saline). Levels of blood A␤ were closely matched in the two groups prior to G-CSF or vehicle treatment.
Evaluation of the histology in NT chimeric mice treated with G-CSF revealed GFPϩ cells in meningeal and cortical blood vessels, but these circulating bone marrow-derived cells rarely infiltrated brain parenchyma (Fig. 5C ). In the chimeric Tg mice, GFPϩ cells decorated amyloid deposits in EC in both G-CSF treated and saline control mice, and visual inspection showed an increased abundance of GFPϩ cells surrounding amyloid deposits in the G-CSF group (Fig. 5A) . Similarly, GFPϩ cells surrounded and infiltrated amyloid deposits in H in both the G-CSF group and saline-treated Tg mice (Fig. 5B) . GFPϩ cells surrounding and infiltrating ␤-amyloid plaques were observed to be transformed into amyloid-ingesting macrophages (Fig. 5C ). The actual numbers of GFPϩ cells that penetrated brain parenchyma were not counted in these immunostained sections because of difficulty distinguishing individual GFPϩ cells around A␤ plaques and a limited number of mice per condition that survived bone marrow grafting for this experiment. Quantitative estimates of the number of GFPϩ cells that infiltrate the brain may be done in the future using fluorescence activated cell sorting (FACS) as described by others (Cardona et al., 2006) . Despite the absence of quantitation, these immunofluorescent images from chimeric mice, taken in the context of the significantly increased microgliosis evidenced by Iba1 immunoreactivity, suggest that G-CSF increases microglial activity in part by recruitment of bone marrow-derived microglia.
G-CSF increases synaptophysin immunostaining in H of both normal and Tg mice
The loss of synapses, particularly the associated presynaptic vesicle protein synaptophysin in the H and association cortices, is considered to be a robust correlate of Alzheimer's disease-associated cognitive decline. As a molecular marker for the presynaptic vesicle membrane, synaptophysin has been widely used in both animal models and human patients. Therefore, the relationship between amyloid reduction and synaptophysin immunostaining was explored. Brain sections from the CA1 and CA3 region of the H were quantitatively analyzed for synaptophysin immunostaining using optical densitometry. This method has been previously reported to reflect the number of synaptophysin immunoreactive nerve terminal boutons in the hippocampal formation (Li et al., 2002) . The optical density of synaptophysin immunohistochemical labeling was reported to be linearly correlated with number of synaptophysin-immunoreactive terminals (R 2 ϭ0.99) (Li et al., 2002) . As shown in Fig. 6 , G-CSF treatment enhanced the optical density of synaptophysin immunostaining in H for both NT and Tg mice, and in both 14.5 month (A) and 8.5 month old (B) cohorts. Interestingly, increased synaptophysin immunostaining was evident between NT and Tg controls, which we have previously reported and determined to be due to aberrant synaptic terminal staining in Tg mice, particularly on the periphery of A␤ deposits . Photomicrographic examples depicting G-CSF's enhancement of hippocampal synaptic area in the CA1 regions of H are presented in Fig. 6C .
G-CSF administration increases hippocampal neurogenesis in Tg mice
The ligand and receptor for G-CSF are widely expressed in neurons and by adult NSCs (Schneider et al., 2005; Zhao et al., 2007) . It is reasonable to expect that G-CSF will have direct actions on those cells, especially since it is known that G-CSF is actively transported into the CNS (Zhao et al., 2007) and in view of our finding measurable levels of hG-CSF in brains from mice of these studies. Adult hippocampal NSCs isolated from normal adult mice and grown in cell culture express the G-CSF receptor (Fig.  7A) . Addition of G-CSF to neural stem cell cultures resulted in a dose-dependent increase in DNA synthesis (Fig. 7B) . To determine if G-CSF had an effect on neuro- (Fig. 8) .
DISCUSSION
This study provides clear evidence that G-CSF administration can reverse cognitive impairment in a commonly used AD mouse model (APPϩ PS1 Tg mice). Moreover, GCSF-induced cognitive benefits appear to involve both A␤-dependent and A␤ independent mechanisms, including activation of brain microglia, recruitment of bone marrow-derived microglia, peripheral anti-inflammatory actions, enhancement of synaptophysin immunoreactivity and increased neurogenesis. With only a short 2½ week course of treatment, Tg mice markedly improved perfor- mance in a challenging test of hippocampal-dependent working memory (the RAWM). This nootropic effect was associated with a marked and rapid reversal of brain A␤ pathology, as evidenced by both decreased A␤ deposition in H and entorhinal cortex, as well as significantly decreased soluble A␤ within H. The robust reduction in A␤ deposits was associated with increased microgliosis as measured by quantitative Iba1 immunostaining. This microglial activation occurred without induction of a CNS or global pro-inflammatory response-indeed, GCSF provided strong anti-inflammatory actions in plasma of Tg mice. The accumulation of brain A␤ with time is clearly associated with cognitive decline. The APPϩ PS1 mice used in this study have been shown previously to become cognitively impaired by 5-6 months of age in a variety of tasks spanning multiple cognitive domains, including the RAWM task of working (short-term) memory utilized in the present study (Arendash et al., 2001a; Jensen et al., 2005) . Accompanying this cognitive impairment in APPϩ PS1 mice are increasing brain levels of both soluble and insoluble A␤1-40 and A␤1-42 beginning in young adulthood. Early ␤-amyloid plaque formation is evident in both cerebral cortex and H by 5-6 months of age and is prominent by 10 -11 months of age in these brain areas critical to cognitive function Ethell et al., 2006) . Thus, G-CSF was administered to 8 and 14 month old APPϩ PS1 mice in the present study at an age wherein A␤ deposition is marked and cognitive impairment is widespread across tasks.
The RAWM task is particularly sensitive to brain A␤ deposition/levels, with strong correlations consistently being present between brain A␤ deposition/levels and RAWM performance in APPϩ PS1 mice at the ages evaluated in the present study (Arendash et al., 2001a; Ethell et al., 2006) . It was therefore no surprise that the substantial reduction in brain A␤ deposition and A␤ levels was associated with cognitive improvement in these Tg mice. This improvement was seen across multiple measures of working memory in the RAWM task. It should be underscored that A␤ aggregation involves a continuum from soluble (dimeric, oligomeric) through aggregated (diffuse, compact) forms. In this context, we have found correlations between cognitive impairment and both soluble and deposited forms of A␤ in multiple prior studies (Arendash et al., 2001b (Arendash et al., , 2004 Costa et al., 2007; Cao et al., 2009) leading us to conclude that the entire process of A␤ aggregation impacts cognitive function. Nonetheless, recent studies have suggested that soluble forms of A␤ are more toxic than deposited A␤ forms (Walsh and Selkoe, 2004) . In addition, brain injections of medium containing soluble A␤ moieties inhibit long-term potentiation in rats (Walsh et al., 2002) . The ability of G-CSF to decrease both brain A␤ deposition and soluble A␤ is best appreciated in the context of the dynamic equilibrium between deposited A␤ and soluble A␤ in the brain (Fig. 9 ). As such, the effect of G-CSF treatment to reduce soluble A␤ levels in Tg mouse brains would appear to be secondary to the primary action of G-CSF to reduce A␤ deposition, resulting in a flux of A␤ from the soluble to the deposited brain pool. This could result in less uni-directional flux of soluble A␤ from brain to blood, although not reflected as an actual decrease in blood A␤ levels chronically.
Other therapeutics that decrease brain A␤ deposition/ levels have also been shown to improve cognitive function. Active and passive immunization with different forms of A␤ using various protocols has been shown to decrease brain A␤ levels/deposition and to improve cognitive performance in various AD Tg mouse lines (Bard et al., 2000) ; review by (Zhang and Ma, 2003) . Leuprolide acetate (a gonadotropin-releasing hormone analogue) administration mediated a reduction of A␤ and this effect correlated with improved cognition in a Tg model of AD (Casadesus et al., 2006) . Moreover, long-term caffeine administration reduces brain A␤ levels and protects against otherwise inevitable cognitive impairment in the Alzheimer's Tg mice .
The GCSF-induced microglial activation that we presently report appears to be a result of direct stimulation of resident microglia which are known to express G-CSF receptor (Hasselblatt et al., 2007) and to some extent, mobilization of microglia from bone marrow-derived cells. Microglia surround and infiltrate amyloid plaques in Tg mouse models of AD (Meda et al., 1996; Ishizuka et al., 1997; Janelsins et al., 2005; Bolmont et al., 2008) . Indeed, perhaps as many as 10% of microglial cells associated with amyloid plaques originate from the bone marrow, with both A␤1-40 and A␤1-42 isoforms triggering this chemo attraction (Simard et al., 2006) . These newly recruited cells also exhibit a specific immune reaction to both exogenous and endogenous A␤ in the brain (Malm et al., 2005; Simard et al., 2006) . In the present study, G-CSF treatment appeared to enhance microglial activity, even in the Tg APPϩ PS1 mice that did not receive irradiation or bone marrow transplantation. The ability of G-CSF to enhance mobilization/recruitment of "new" bone marrow-derived microglia may be particularly important in view of a recent study showing that, as APPϩ PS1 mice age, their microglia become dysfunctional by exhibiting significantly reduced expression of A␤-binding receptors and A␤-degrading enzymes (Hickman et al., 2008) . Since these microglia from aged APPϩ PS1 mice nonetheless maintain their ability to produce pro-inflammatory cytokines, it is important to underscore that the augmented microglial activity triggered by G-CSF administration was not associated with a global inflammatory response.
G-CSF, which is known to increase neutrophil differentiation in the periphery, modulates the immune response by inhibiting the production or activity of the main proinflammatory mediators (Hartung, 1998; Boneberg et al., 2000) . The functional activity of G-CSF receptors in peripheral blood cells has been shown by challenging isolated leukocyte populations to release cytokines with endotoxin in the presence of G-CSF (Boneberg et al., 2000) . For example, G-CSF treatment attenuated the release of the proinflammatory cytokines TNF-␣, IL-12, IL-1␤, and IFN-␥ in ex vivo lipopolysaccharide (LPS)-stimulated whole blood. Hence the potential pro-inflammatory effect of increasing the circulating neutrophil population by G-CSF is modulated by inhibition of pro-inflammatory cytokine release.
Through a mechanism that may have both A␤ dependent and A␤-independent components, G-CSF's ability to increase synaptic area, as reflected by increased optical density of synaptophysin immunostaining, could be critical for the recovery of Tg mice from cognitive dysfunction. Even NT mice treated with G-CSF showed an increase in hippocampal synaptophysin immunostaining. This novel observation of increased synaptic area with G-CSF treatment is important for several reasons. Synapse pathology is considered by many experts to be a major correlate of cognitive decline not only in AD patients, but also in other dementia syndromes (DeKosky and Scheff, 1990; Terry et al., 1991; Dickson et al., 1995; Terry, 1996; Scheff and Fig. 9 . Diagrams depicting proposed effects of G-CSF treatment on the dynamic equilibrium between soluble and deposited A␤ in the brain (unmodulated). Newly produced A␤, resulting from the actions of both ␤-and ␥ secretase on APP, enters an equilibrium between soluble and deposited (insoluble) A␤ in the brain. Some bone marrow-derived microglia surround A␤ plaques (green), continually engulfing deposited A␤. Transport of soluble A␤ from brain to blood plasma is concentration-dependent on levels of soluble A␤ in the brain (G-CSF treatment). A relatively short course of G-CSF treatment increases the penetration of bone marrow-derived microglia (green) into the brain and increases activation of reside brain microglia, thus enhancing A␤ engulfment (removal) from plaques. This causes a shift "to the right" in the equilibrium between soluble A␤-deposited A␤, decreasing soluble levels of brain A␤ and resulting in less soluble A␤ transport into the blood. For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article. Price, 2003) . The loss of synapses, and particularly the associated presynaptic vesicle protein synaptophysin in the H and association cortices is considered a consequence of A␤ deposition. However, loss of synaptophysin and impaired synaptic function has been reported to occur before the onset of A␤ deposition in Tg mice (Hsia et al., 1999; Mucke et al., 2000; Oddo et al., 2003) .
On the other hand, A␤ plaques and deposition have been reported to disrupt neuronal circuitry and therefore may indirectly affect global synaptic function (Stern et al., 2004) or cognitive function (Chen et al., 2000) . Support for the hypothesis that A␤ deposition results in synaptic dysfunction was provided by reports that reduction in amyloid load by immunization protected against progressive loss of synaptophysin in the hippocampal molecular layer and frontal neocortex of a Tg mouse model of Alzheimer's disease (Buttini et al., 2005) . These results were substantiated by quantitative electron microscopic analysis of synaptic density and strongly support a direct causative role of A␤ in the synaptic degeneration seen in AD. In addition, amyloid plaques and neuritic lesions were reversed within a short period of time after administration of a single dose of A␤ antibody to Tg APP mice (Lombardo et al., 2003) . Amyloid clearance and recovery of normal neuronal geometries were observed as early as 4 days and lasted at least 32 days after a single treatment. These results suggest that neuronal and synaptic morphology is self-correcting after amyloid is cleared (Lombardo et al., 2003) . Our future studies will determine whether GCSF's ability to increase synaptic immunoreactivity in Tg mice within several weeks is a reflection of increased synaptic number (e.g. synaptogenesis) or some other mechanism of synaptic action (e.g. enlargement of existing synapses). In any event, effects of G-CSF on hippocampal LTP are critical and are currently being studied in our laboratories.
It is important to underscore that G-CSF does more than activate resident microglia and possibly increase trafficking of microglia from marrow to brain to presumably decrease brain A␤ deposition through enhanced phagocytotic activity. G-CSF readily passes through the bloodbrain barrier (Zhao et al., 2007) and has been shown to act directly on neural tissue via interaction with G-CSF receptors expressed by neurons and neural stem cells (Schneider et al., 2005) . Both the G-CSF ligand and its receptor are widely expressed by brain neurons (as well as microglia) and their expression is induced by ischemia. In the present study, we verified that administered hG-CSF does indeed enter the brain. Through CNS actions, administered hG-CSF thus increased the generation of new neurons in H, as indicated by increased numbers of calretininexpressing cells in the DG.
Increased neurogenesis and associated synaptogenesis promoted by G-CSF may be the neural substrate for the improved cognition. However, the relationship between cognitive performance and neurogenesis in the Tg APP/ PS1 mouse is uncertain. Tg APP/PS1 mice raised in enriched environments exhibited increased cognitive performance and an increased rate of hippocampal NSC proliferation when compared to Tg APP/PS1 mice raised in an "impoverished" environment (Catlow et al., 2009 ). However, the number of BrdU birth-dated cells and calretininexpressing cells that survived two weeks after BrdU injection was not different between the groups of Tg mice (Catlow et al., 2009) . A recent review of neurogenesis in various Tg mouse models of AD reveals conflicting results in the literature, with reports of increases, no effect and decreases in hippocampal neurogenesis depending on the mouse model, age, temporal parameters and assay methods (Kuhn et al., 2007) . Given the uncertainty regarding the relationship between neurogenesis, cognitive performance and amyloid deposition in Tg AD models, increased neurogenesis may play a role, but cannot be cited as the critical mechanism at this time, for improved cognitive function produced by G-CSF administration.
Of direct relevance to the present study, G-CSF administration was recently reported to have pro-cognitive effects without reducing either soluble or deposited forms of A␤ in the brains of AD Tg mice (Tsai et al., 2007) . A 5-day regimen of G-CSF administered to Tg2576 mice was reported to result in improved learning (acquisition) in the Morris water maze task (Tsai et al., 2007) . In their study, Tsai et al. (2007) behaviorally evaluated mice after stopping G-CSF treatment and only a single reference learning measure was evaluated. In contrast, the present study utilized multiple measures/endpoints in a very challenging working memory task (the RAWM) that is highly sensitive to both soluble and deposited brain A␤. Moreover, G-CSF treatment was continued throughout behavioral testing and until mice were euthanized. This methodology, in addition to higher doses of G-CSF administered over a longer period of time, is probably why we were able to demonstrate G-CSF induced decreases in brain A␤ levels/deposition, while Tsai et al. (2007) reported no effects of G-CSF treatment on brain A␤. Despite these differences in effects of G-CSF on total plaque burden, both reports found improvement in cognitive performance, underscoring the uncertain relationship between cognitive function and amyloid burden. An interesting finding in Tsai et al. (2007) report was an increase in the number of BrdU-labeled neurons located around A␤ plaques in cerebral cortex and H. The authors suggested that these new neurons were derived from hematopoietic stem cells that had infiltrated the brain and perhaps the behavioral improvement was related to increased neurogenesis. "Transdifferentiation" of bone marrow-derived cells has been reported, but is considered to be a rare phenomenon and may represent fusion of bone marrow-derived cells with injured neurons (Alvarez-Dorado et al., 2003) .
CONCLUSIONS
To summarize results of the present study, G-CSF administration impacts both the bone marrow and the CNS, resulting in reversal of cognitive deficits associated with brain A␤ reduction, increased synaptophysin immunostaining, and neurogenesis. Additionally, G-CSF reduces inflammation by suppressing production/activity of major pro-inflammatory cytokines in plasma, consistent with pre-vious reports not involving AD Tg mice (Hartung, 1998; Solaroglu et al., 2007) . As underscored previously, the cognitive benefits of G-CSF may involve not only induction of A␤-reducing phagocytotic activity, but also multiple mechanisms of "neuroprotection" and neuroplasticity (e.g. reduction of inflammation, stimulation of neurogenesis and synaptogenesis). Indeed, G-CSF has been shown to be protective against loss of dopaminergic neurons in an animal model of Parkinson's disease-the MPTP-treated mouse (Meuer et al., 2006) . Of direct importance to AD, decreased blood levels of G-CSF are one of 18 plasma biomarkers found to identify MCI patients who progressed to AD within a few years (Ray et al., 2007) . In characterizing the physiologic categories of these 18 biomarkers, the authors point to "systemic dysregulation" of hematopoiesis, apoptosis, neuroprotection, and inflammation as key indicators of pre-symptomatic AD. Not coincidentally, G-CSF would appear to favorably impact all four of these physiologic categories. Additional research is under way in our laboratories to clarify the pleiotropic actions of G-CSF upon brain and peripheral tissues, specifically as they relate to AD.
The multiplicity of beneficial mechanisms provided by GCSF, in combination with its inherent safety through use in other medical conditions such as leukopenia, makes this HGF a most attractive candidate for clinical trials in AD.
